Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

Current maintenance or controller treatments for COPD include tiotropoium, LAMA, LABA, LABA + ICS, LAMA + LABA, roflumilast, theophylline, and 'triple therapy' combining LAMA + LABA + ICS.

Nearly 50% of patients were initially prescribed LABA/inhaled corticosteroids. BOSTON — Compared with 17,800 patients starting new inhaled COPD maintenance therapy in 2016, 32,558 patients ...

The near-term pipeline for COPD has several ICS, LABA and LAMA combinations in development with claims of improved efficacy and better safety profiles. Moreover, the development of more innovative ...

is more effective than a LABA combined with an inhaled corticosteroid (ICS) in moderate-to-severe COPD. In the study Spiolto - which combines tiotropium, the active ingredient in Boehringer's LAMA ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first ...

In the CRYSTAL study, patients with moderate COPD who were switched to Ultibro Breezhaler from their previous therapy (LABA+ICS * or LABA or LAMA) experienced superior improvements in lung ...

Black Americans have a higher likelihood of having asthma-COPD overlap syndrome (ACOS) but may not know it. Here’s what you ...

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

The Spanish COPD guidelines recommend treatment of the ... to ICS + long-acting b2 agonist (LABA) combination for 'triple therapy'. In even more severe cases, theophylline or roflumilast may ...